Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia.
Andrea Eleazar, MHS
Advertisement
Andrea Eleazar, MHS, is an assistant editor for Targeted Oncology, with interests in noncommunicable diseases, health equity research, and global health. Eleazar holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Articles by Andrea Eleazar, MHS
A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma (MM), highlighting the impact of overweight status on efficacy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
House Republicans Block Vote on ACA Subsidy Extension
2
Study Suggests Adding BTKi to Chemo May Improve Early Outcomes in Richter Transformation in CLL
3
Zasocitinib Hits Phase 3 End Points in Plaque Psoriasis
4
FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC
5
